Genmab — August 2019
-
Om DLBCL,FL,MCL studiet:The study also experienced a high screen failure rate, where only 63 (56%) of 112 screened patients with available tumor samples had CD38 expression ≥ 50% across all 3 NHL cohorts. Among these patients with CD38 expression ≥ 50%, only 36 were eligible for study enrollment, questioning the generalizability of the study population.
-
targeting CD38 may still have potential as a treatment for NHL subtypes in different patient populations or by using different anti-CD38 treatment strategies.36 A threshold for CD38 expression remains to be defined, and the role of synergistic activity in combination with other therapies, such as rituximab, CHOP, or lenalidomide
-
-
Basedannelsen forsætter stille og roligt. Alt er som det skal være i en sund uptrend. God weekend til alle.
-
Vi lukkede da i -0,18%
-
1376...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind